⚠️ Warnings
If an allergic reaction occurs during treatment, therapy must be discontinued immediately.
Areas treated with the cream should not be covered with an occlusive dressing unless strictly necessary. Local and systemic toxicity is common, particularly with prolonged continuous use over extensive areas of damaged skin, in flexures, or under polyethylene occlusion. When used in children or on the face, treatment must be limited to 5 days. Prolonged continuous treatment is undesirable in all patients regardless of age.
The cream must not be applied to the eyes or the periorbital area because of the risk of cataract, glaucoma, fungal eye infections, and exacerbation of herpes.
Certain body areas, such as the groin, axillae, and perianal region, are more prone to the development of striae during treatment with Belogent. Application to these areas must therefore be kept as brief as possible.
Do not use to treat wounds or leg ulcers.
Systemic absorption of betamethasone dipropionate may induce reversible suppression of the hypothalamic-pituitary-adrenal (HPA) axis, with the potential for glucocorticoid insufficiency after discontinuation of treatment. Some patients may develop Cushing's syndrome. Patients receiving high doses of potent corticosteroids over extensive skin areas should be regularly evaluated for HPA axis function. If signs of HPA axis suppression appear, treatment should be discontinued, the dosing frequency reduced, or the product substituted with a less potent corticosteroid.
Recovery of HPA axis function after dose reduction is usually rapid and complete. Rarely, symptoms of corticosteroid withdrawal similar to those seen with systemic therapy may occur.
Use in children: Children may be more susceptible than adult patients to topical corticosteroid-induced HPA axis suppression and to exogenous corticosteroid effects, owing to greater absorption resulting from a higher body surface area-to-body weight ratio.
Belogent cream may be used to treat diaper dermatitis only when strictly necessary.
If fungal superinfection of the lesions occurs, additional antifungal therapy is required.
Long-term topical use of gentamicin may lead to bacterial resistance to aminoglycosides. For this reason, topical gentamicin is not recommended in immunosuppressed patients or other high-risk groups. If resistance or secondary infection develops during treatment, the product must be discontinued and appropriate therapy initiated.
Visual disturbance
Visual disturbance has been reported with both systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, referral to an ophthalmologist for evaluation of possible causes should be considered, including cataract, glaucoma, or rare conditions such as central serous chorioretinopathy (CSCR), which have been reported following both systemic and topical corticosteroid administration.
This product contains cetostearyl alcohol, which may cause local skin reactions (e.g., contact dermatitis), and chlorocresol, which may cause allergic reactions.
